InsiderTrades.com logo
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings   |   Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
William D. Turner net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

William Turner Biography and Net Worth

Insider of Sierra Oncology
William D. Turner serves as Chief Regulatory and Technical Operations Officer of the Company. Mr. William Turner has more than 25 years of drug development and drug commercialization experience, leading organizations through all phases of product development including commercial drug process, method and facility validations, all phases of clinical programs, numerous drug application filings and several global approvals. William was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years. Prior to that, he served as Vice President of Regulatory Affairs and Global Quality at Dynavax Technologies Corporation as well as several years in a leadership position at MedImmune (now AstraZeneca). He has significant experience in both small molecule and biologic development and has led teams in many therapeutic areas including vaccinology, oncology, hematology, allergy and respiratory. Mr. Turner holds a degree in Medical Microbiology with a minor in Chemistry from California State University at Long Beach .

How old is William D. Turner?

Mr. Turner is currently 56 years old. There are 5 older executives and no younger executives at Sierra Oncology. The oldest executive at Sierra Oncology is Dr. Barbara J. Klencke M.D., Chief Medical Officer, who is 65 years old. Learn More on William D. Turner's age.

How do I contact William D. Turner?

The corporate mailing address for Mr. Turner and other Sierra Oncology executives is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. Sierra Oncology can also be reached via phone at (604) 558-6536 and via email at [email protected]. Learn More on William D. Turner's contact information.

Has William D. Turner been buying or selling shares of Sierra Oncology?

William D. Turner has not been actively trading shares of Sierra Oncology in the last ninety days. Most recently, William D. Turner sold 100 shares of the business's stock in a transaction on Tuesday, April 5th. The shares were sold at an average price of $37.09, for a transaction totalling $3,709.00. Learn More on William D. Turner's trading history.

Who are Sierra Oncology's active insiders?

Sierra Oncology's insider roster includes Gaurav Aggarwal (Director), Craig Collard (Director), Stephen Dilly (CEO), Mary Thomson (General Counsel), and William Turner (Insider). Learn More on Sierra Oncology's active insiders.

William D. Turner Insider Trading History at Sierra Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2022Sell100$37.09$3,709.00View SEC Filing Icon  
3/17/2022Sell3,453$37.06$127,968.18View SEC Filing Icon  
2/7/2022Sell10,000$32.32$323,200.00View SEC Filing Icon  
1/26/2022Sell5,000$27.05$135,250.00View SEC Filing Icon  
See Full Table

William D. Turner Buying and Selling Activity at Sierra Oncology

This chart shows William D Turner's buying and selling at Sierra Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sierra Oncology Company Overview

Sierra Oncology logo
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $54.99
Low: $54.99
High: $54.99

50 Day Range

MA: $54.93
Low: $54.73
High: $54.99

2 Week Range

Now: $54.99
Low: $14.91
High: $55.19

Volume

N/A

Average Volume

931,731 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings   |   Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself